Alvion Pharmaceuticals

Alvion Pharmaceuticals is a science-driven and intellectual property powerhouse, propelling rapid growth in the pharmaceutical industry by developing and manufacturing an extensive portfolio of proprietary products in cardiology, diabetes, central nervous system, urology and others. Partnering with cutting-edge R&D centers, Alvion operates as a private and independent company, focusing on the research and development of non-infringing generics and added-value medicines. With a diversified business model, Alvion is filling and supplying medicines to its licensing pharmaceutical partners (B2B) worldwide. Our commitment to excellence has enabled us to license our products and services across all Europe, MENA, Canada, Australia, South Africa, APAC, and LATAM, supporting a robust business model. With headquarters in Athens, Greece and offices in Ireland and South Africa, Alvion stands as a preferred B2B partner for multinationals and major pharmaceutical companies globally (supplying via WDA Accreditation). We pride ourselves on being one of Southern Europe's most passionate and customer driven pharmaceutical companies, aiming to be vertically integrated by 2029. For pharmacovigilance inquiries, please contact us at pv@alvionpharma.com. Want to learn more about Alvion Pharmaceuticals? Visit us at or reach out to us at bd@alvionpharma.com.